Drugs / SA5Ag
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04420221 | Nov 2022 → Mar 2024 | skin infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SA5Ag | “the five-antigen S. aureus vaccine (SA5Ag), half or full antigen doses, unadjuvanted or with AS01E adjuvant” PMID 41800789 ↗ Mar 2026 |
| Known as | SA5Ag-Adj | “two full doses of AS01E-adjuvanted SA5Ag (SA5Ag-Adj) or placebo, 2 months apart” PMID 41800789 ↗ Mar 2026 |
| Modality | Vaccine | “five-antigen S. aureus vaccine” PMID 41800789 ↗ Mar 2026 |
| Route | Intramuscular | “administered intramuscularly” NCT04420221 ↗ |